Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity
I'm PortAI, I can summarize articles.
Touyun Biotech Group Limited (HK:1332) announced a strategic cooperation agreement to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028. This comes amid unusual market activity, with a significant increase in share price and trading volume. The company confirmed its operations remain normal. The latest analyst rating for the stock is a Hold with a price target of HK$0.50. The current market cap is HK$1.08B, with an average trading volume of 1,589,265.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments